IR Contact

Lexaria Bioscience → Investor Relations → IR Contact

☰

Overview
Press Releases
Events & Presentations
Company Info
Analyst Coverage
Stock Data
Financial Info
Legend Removal
Governance
Resources

IR Contact

Investor Relations

Auditor

Transfer Agent

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
[email protected]

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
105 Peach State Court, Suite A
Tyrone, GA 30290

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More